Shady Nafie1, Raj P Pal, John P Dormer, Masood A Khan. 1. Department of Urology, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW, UK, shady.nafie@me.com.
Abstract
BACKGROUND: The possibility of prostate cancer as a cause for steadily rising PSA despite previously negative transrectal ultrasound (TRUS)-guided prostate biopsies is a major concern. An initial negative TRUS-guided prostate biopsy does not necessarily exclude the presence of clinically significant prostate cancer. We determined the role of transperineal template prostate biopsy (TPTPB) in prostate cancer detection in men with raised PSA despite two previous sets of negative TRUS biopsies. METHODS: Between January 2008 and August 2012, a total of 122 men's records were reviewed after having 36-core TPTPB following two previous sets of negative TRUS biopsies despite raised PSA. A retrospective record of PSA levels, clinicopathological parameters and histological outcomes was made. RESULTS: Mean age was 63 years (range 49-77), and mean PSA was 18.0 (range 2.0-119.0). A total of 71/122 (58 %) men were diagnosed with prostate cancer on TPTPB. Of these, 28 (39 %), 34 (48 %), 5 (7 %), and 4 (6 %) had Gleason score 6, 7 (3 + 4), 7 (4 + 3), and 9 (4 + 5), respectively. The mean number of positive cores was 7 (range 1-22). Of these, only 15 (21 %) had ≤2 cores positive and Gleason score of 6. Of the 51 (42 %) men with a negative histology on TPTPB, 11 (22 %), 10 (19 %), and 30 (59 %) had atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, or benign pathology. CONCLUSION: TPTPB is associated with a high rate of clinically significant prostate cancer diagnosis (58 %) in men with raised PSA despite two previous sets of negative TRUS biopsies.
BACKGROUND: The possibility of prostate cancer as a cause for steadily rising PSA despite previously negative transrectal ultrasound (TRUS)-guided prostate biopsies is a major concern. An initial negative TRUS-guided prostate biopsy does not necessarily exclude the presence of clinically significant prostate cancer. We determined the role of transperineal template prostate biopsy (TPTPB) in prostate cancer detection in men with raised PSA despite two previous sets of negative TRUS biopsies. METHODS: Between January 2008 and August 2012, a total of 122 men's records were reviewed after having 36-core TPTPB following two previous sets of negative TRUS biopsies despite raised PSA. A retrospective record of PSA levels, clinicopathological parameters and histological outcomes was made. RESULTS: Mean age was 63 years (range 49-77), and mean PSA was 18.0 (range 2.0-119.0). A total of 71/122 (58 %) men were diagnosed with prostate cancer on TPTPB. Of these, 28 (39 %), 34 (48 %), 5 (7 %), and 4 (6 %) had Gleason score 6, 7 (3 + 4), 7 (4 + 3), and 9 (4 + 5), respectively. The mean number of positive cores was 7 (range 1-22). Of these, only 15 (21 %) had ≤2 cores positive and Gleason score of 6. Of the 51 (42 %) men with a negative histology on TPTPB, 11 (22 %), 10 (19 %), and 30 (59 %) had atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, or benign pathology. CONCLUSION:TPTPB is associated with a high rate of clinically significant prostate cancer diagnosis (58 %) in men with raised PSA despite two previous sets of negative TRUS biopsies.
Authors: Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell Journal: Acta Oncol Date: 2011-06 Impact factor: 4.089
Authors: J Stephen Jones; Amit Patel; Lynn Schoenfield; John C Rabets; Craig D Zippe; Cristina Magi-Galluzzi Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: Simon R J Bott; Alastair Henderson; James E Halls; Bruce S I Montgomery; Robert Laing; Stephen E M Langley Journal: Urology Date: 2006-11-07 Impact factor: 2.649
Authors: A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner Journal: Prostate Cancer Prostatic Dis Date: 2009-09-29 Impact factor: 5.554
Authors: Simon P Hood; Georgina Cosma; A Graham Pockley; Gemma A Foulds; Catherine Johnson; Stephen Reeder; Stéphanie E McArdle; Masood A Khan Journal: Elife Date: 2020-07-28 Impact factor: 8.140
Authors: Georgina Cosma; Stéphanie E McArdle; Gemma A Foulds; Simon P Hood; Stephen Reeder; Catherine Johnson; Masood A Khan; A Graham Pockley Journal: Front Immunol Date: 2021-12-16 Impact factor: 7.561
Authors: Georgina Cosma; Stéphanie E McArdle; Stephen Reeder; Gemma A Foulds; Simon Hood; Masood Khan; A Graham Pockley Journal: Front Immunol Date: 2017-12-18 Impact factor: 7.561